China’s homegrown COVID-19 drugs expected for delivery within month after conditional approval

This pill, VV116, is an anti-viral medication for use in adults with mild to moderate COVID symptoms. Clinical data suggests that the drug can significantly shorten the duration of the disease when compared to placebo, with a lower incidence of adverse effects. Professor Shen Jingshan and his research team have been developing the drug since January 2020. The clinical tests and marketing are being conducted by the pharmaceutical company Junshi Biosciences and Vigonvita Life Sciences. Production of the drug is on the way and the first batches are expected to be delivered within a month. The new medications have been described as a breakthrough in China’s pharmaceutical industry. The Shanghai Institute of Materia Medica was also involved in developing the antiviral pill XIANNUOXIN. __________________ ShanghaiEye focuses on producing top-quality contents. Nobody knows SHANGHAI better than us. Please subscribe to us ☻☻☻ ______________